Davis R M Inc. Buys 4,195 Shares of Eli Lilly and Company $LLY

Davis R M Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 8.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,162 shares of the company’s stock after purchasing an additional 4,195 shares during the period. Davis R M Inc.’s holdings in Eli Lilly and Company were worth $42,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in LLY. Altman Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 4.1% in the 2nd quarter. Altman Advisors Inc. now owns 1,791 shares of the company’s stock valued at $1,390,000 after buying an additional 70 shares in the last quarter. Compass Capital Management Inc. lifted its position in Eli Lilly and Company by 6,991.2% during the second quarter. Compass Capital Management Inc. now owns 18,437 shares of the company’s stock valued at $14,372,000 after acquiring an additional 18,177 shares during the last quarter. ProShare Advisors LLC boosted its stake in Eli Lilly and Company by 13.0% in the second quarter. ProShare Advisors LLC now owns 145,830 shares of the company’s stock valued at $113,679,000 after acquiring an additional 16,805 shares in the last quarter. Profund Advisors LLC grew its holdings in Eli Lilly and Company by 8.7% in the second quarter. Profund Advisors LLC now owns 12,758 shares of the company’s stock worth $9,945,000 after purchasing an additional 1,024 shares during the last quarter. Finally, King Luther Capital Management Corp grew its holdings in Eli Lilly and Company by 11.3% in the second quarter. King Luther Capital Management Corp now owns 166,483 shares of the company’s stock worth $129,778,000 after purchasing an additional 16,841 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. BMO Capital Markets raised their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday. Guggenheim restated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $960.88.

Eli Lilly and Company Stock Down 1.5%

LLY stock opened at $923.35 on Monday. The company has a market capitalization of $872.92 billion, a P/E ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $955.46. The firm’s fifty day simple moving average is $799.97 and its 200-day simple moving average is $775.01. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Insider Buying and Selling

In related news, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 4,314 shares of company stock worth $2,766,929 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.